Previous Page Next Page

Several TRK inhibitors are in clinical development or have been licensed in some countries. These agents differ in stage of development, characteristics, and mode of action, as well as whether they address acquired resistance to TRK protein inhibition. 

Click on the links below to find out more about acquired resistance to TRK protein inhibition, as well as first-generation and next-generation TRK inhibitors that are either licensed or under development.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings